GENova Biotherapeutics Enters Collaboration Agreement With Prime BioResearch

GENova Biotherapeutics (GENova) has signed a collaboration agreement with Prime BioResearch (Prime BioResearch), the agreement is focused on how personalised medicine can be applied to cure cancer.

The company expects that the deal between GENova and Prime BioResearch will put GENova to the forefront on personalised cancer treatments and enable GENova to make a place in personalised medicines market.

Aaron Whiteman, CEO for GENova, said: “Prime BioResearch knows that each patient is unique, and that not every person with the same disease responds to each drug in exactly the same way. They use biomarker information to determine a patient’s potential responsiveness to each drug and to maximise treatment and eliminate possible adverse reactions.”

The companies are confident that through scientific collaboration in the field of personalised medicines, they will expedite their drug development activities and subsequently license the technology to companies like Pfizer, Merck, Eli Lilly, Sanofi, Roche, and GSK.